StocksFin Logo
Bio-Techne Corporation country of incorporation
|
|
Mr. Charles Kummeth
|
3,000 employees
NASDAQ | Healthcare | Biotechnology
Alnylam Pharmaceuticals, Inc. country of incorporation
|
|
Dr. John Maraganore
|
1,665 employees
NASDAQ | Healthcare | Biotechnology
Q123 reported Nov 7, 2022 Reporting Period
$269.66M 4.6% vs. Q122 Revenues Q123
66.6% 0.4% vs. Q122 Gross Profit Margin
33.21% 22.9% vs. Q122 Net Profit Margin
46.53M -3.9% vs. Q122 Free Cash Flow Q123
$0.55 30.6% vs. Q122 EPS Q123
Period
Profitable?
Revenue Growth?
Net Profit Growth?
FCF Growth?
OCF Growth?
EPS Growth?
Pays Dividend?
Q123
0.11%
Q322
Q322 reported Oct 27, 2022 Reporting Period
$264.31M 40.9% vs. Q321 Revenues Q322
84.44% 2.2% vs. Q321 Gross Profit Margin
-153.58% ! -40.9% vs. Q321 Net Profit Margin
-131.79M ! 1.7% vs. Q321 Free Cash Flow Q322
$-3.32 ! -93% vs. Q321 EPS Q322
-
Period
Profitable?
Revenue Growth?
Net Profit Growth?
FCF Growth?
OCF Growth?
EPS Growth?
Pays Dividend?
Q123
0.11%
Q322
Loading...
Loading...
Loading...
Loading...
Ratios
As of
Sep 30, 2022
Sep 30, 2022
Quick Ratio
2.74
3.17
Current Ratio
4.01
3.48
Cash Ratio
1.2
1.39
Price to Book
6.36
-361.52
Price to Sales
41.32
92.52
Price to Earnings
31.1
-15.06